<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2D8E82C0-85D1-4809-90FC-4716F4AF5865"><gtr:id>2D8E82C0-85D1-4809-90FC-4716F4AF5865</gtr:id><gtr:name>Institute of Food Research</gtr:name><gtr:department>Contracts</gtr:department><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:postCode>NR4 7UA</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2D8E82C0-85D1-4809-90FC-4716F4AF5865"><gtr:id>2D8E82C0-85D1-4809-90FC-4716F4AF5865</gtr:id><gtr:name>Institute of Food Research</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:postCode>NR4 7UA</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1551EA57-1B3D-4A9B-A282-1C5A6C3A2FD4"><gtr:id>1551EA57-1B3D-4A9B-A282-1C5A6C3A2FD4</gtr:id><gtr:firstName>Arjan</gtr:firstName><gtr:surname>Narbad</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C31C6A21-CCF9-4A23-92F8-C071B12A80DA"><gtr:id>C31C6A21-CCF9-4A23-92F8-C071B12A80DA</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Gasson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FF%2F00042196"><gtr:id>C26AE441-0CC2-4727-96EE-EF26262159C4</gtr:id><gtr:title>ISPG Studentship: An investigation into the potential use of bacteriophages in the prevention and treatment of Clostridium difficile associated diarrhoea</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/F/00042196</gtr:grantReference><gtr:abstractText>The project aims to isolate free-living virulent phages that target Clostridium difficile, or genetically modify temperate phages of this bacterial strain to prevent lysogenisation with the host. The project will include experiments to evaluate the use of these phages to de-colonise and treat Clostridium difficile associated diarrhoea.</gtr:abstractText><gtr:fund><gtr:end>2013-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>60800</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>This was a PhD studentship that trained Emma Meader and she gained her PhD degree with three publications to her name. She is now working as a biomedical scientist in an NHS setting and providing a high quality service to the general public. She is continuing research in diagnostics improving the methods for detection of viral infections. 
Research findings have been used to develop additional grant applications for further funding from MRC. 
During the project a number of public engagement activities took place, included interacting with the general public in Norwich where Emma and Arjan Narbad gave lectures to high school pupils and the general public to explain the project. Emma also interacted with Members of Parliament, where she presented her work highlighting the needs for alternatives to antibiotics</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>00EF7D44-A737-4BB3-A204-4B4AD87122D2</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>5464594137f162.16612025</gtr:outcomeId><gtr:sector>Creative Economy,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The development of new antimicrobial agents as an alternative to antibiotics is a matter of worldwide importance; this is due to the rise in multi-drug resistant pathogenic bacteria and the decline in the discovery of new effective antibiotics. Bacteriophages were first discovered by d'Herelle in 1917 and their potential as anti-infective was immediately recognised and Phage therapy treatments initiated against dysentery were very promising. However the discovery of antibiotics resulted in the loss of interest in the phage therapy in the West, although it has continued in Eastern Europe. The aim of this project was to test if phage therapy can be used to control Clostridium difficile, which is a major cause of hospital acquired infection. In this project an artificial model of Clostridium difficile infection was developed using the in vitro model colon and used to test phage efficacyy. We showed that the phage had potential for prophylactic use. However the phage we isolated had the ability to lysogenize, that is it had the ability to hide its DNA within the bacterial chromosome instead of killing hte bacterium, and this limited its use. Nonetheless, we discovered that this process of lysogeny itself disabled the pathogen and it was not able to make the toxin that causes the disease so it still had therapeutic potential.</gtr:description><gtr:exploitationPathways>This phage can still be used as a cocktail with other phages or it can be genetically altered to make it 'lytic' to improve its potential for therapy.</gtr:exploitationPathways><gtr:id>82BEAE66-DA80-4F01-B054-94ED42B90E5B</gtr:id><gtr:outcomeId>546457a8402746.85026644</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>13D9A806-FE0F-4C7B-B5CE-F04BF2EF4478</gtr:id><gtr:title>Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system.</gtr:title><gtr:parentPublicationTitle>Anaerobe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1500f94049a2b61dd012a0d0e33a756"><gtr:id>a1500f94049a2b61dd012a0d0e33a756</gtr:id><gtr:otherNames>Meader E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1075-9964</gtr:issn><gtr:outcomeId>545b999942eba5.49266758</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06684EC4-3BAE-40DF-8CF7-A546E6D4E22A</gtr:id><gtr:title>Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system.</gtr:title><gtr:parentPublicationTitle>Anaerobe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1500f94049a2b61dd012a0d0e33a756"><gtr:id>a1500f94049a2b61dd012a0d0e33a756</gtr:id><gtr:otherNames>Meader E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1075-9964</gtr:issn><gtr:outcomeId>545b99998ef476.27491532</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>488DBA54-5155-438D-A9F3-D11914E52243</gtr:id><gtr:title>Determination of the attP and attB sites of phage CD27 from Clostridium difficile NCTC 12727.</gtr:title><gtr:parentPublicationTitle>Journal of medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6682b85c220c8c8bd534e7066c4856a9"><gtr:id>6682b85c220c8c8bd534e7066c4856a9</gtr:id><gtr:otherNames>Williams R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2615</gtr:issn><gtr:outcomeId>545b9999697788.51146052</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/F/00042196</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>